Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Italy Fines Apple €98.6 Million Over App Store Dominance 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
CLEVELAND, Feb. 09, 2016 -- Athersys, Inc. (Nasdaq:ATHX) will release its year end 2015 financial results at approximately 4:00 PM EST on Thursday, March 10, 2016, and host a conference call shortly thereafter at 4:30 PM EST to review the results. Gil Van Bokkelen, Chairman and Chief Executive Officer, and William (B.J.) Lehmann, President and Chief Operating Officer, will host the call as follows:
| Date | March 10, 2016 |
| Time | 4:30 p.m. (Eastern Time) |
| Telephone access: US and Canada | 800-273-1254 |
| Telephone access: International | 973-638-3440 |
| Access code | 22710392 |
| Live webcast | www.athersys.com under Investors section |
A replay will be available for on-demand listening shortly after the completion of the call until 11:59 PM EDT on March 24, 2016 at the aforementioned URL, or by dialing 800-585-8367 or 855-859-2056 in the U.S. and Canada, or from abroad 404-537-3406, and entering access code 22710392.
About Athersys
Athersys is an international biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product, initially for disease indications in the cardiovascular, neurological, inflammatory and immune disease areas, and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and collaborations with leading pharmaceutical and biotechnology companies, as well as world-renowned research institutions to further develop its platform and products. More information is available at www.athersys.com.
Contact: William (B.J.) Lehmann, J.D. President and Chief Operating Officer Tel: (216) 431-9900 [email protected]
